Effective December 18, 2023, Foquest is listed on the PEI Formulary (special authorization) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Learn more about the eligibility criteria for reimbursement of Foquest in PEI.
Effective December 18, 2023, Foquest is listed on the PEI Formulary (special authorization) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Learn more about the eligibility criteria for reimbursement of Foquest in PEI.